Page 28 - Research Models News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Norris Perne & French LLP MI grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 1.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 102,813 shares of the medical research company’s stock after buying an additional 1,267 shares during the quarter. Charles River Laboratories International […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its price objective trimmed by Robert W. Baird from $267.00 to $256.00 in a report issued on Friday, MarketBeat.com reports. The firm currently has an outperform rating on the medical research company’s stock. Several other equities research analysts have also weighed in on the company. Bank […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its price objective reduced by Bank of America from $245.00 to $230.00 in a report issued on Friday morning, FlyOnTheWall reports. Other equities research analysts have also recently issued research reports about the company. TD Cowen initiated coverage on Charles River Laboratories International in a research […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its target price reduced by Wells Fargo & Company from $280.00 to $275.00 in a research report released on Friday morning, Marketbeat Ratings reports. They currently have an overweight rating on the medical research company’s stock. A number of other equities research analysts have also recently […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its price objective reduced by Guggenheim from $255.00 to $225.00 in a research note published on Friday morning, MarketBeat reports. They currently have a buy rating on the medical research company’s stock. A number of other equities research analysts have also recently weighed in on CRL. […]